Expires September 3, 2017
Epidermal Growth Factor Receptor and Non-Small Cell Lung Cancer 3.0
GREAT DEBATES - CLINICAL CASES - EXPERT PANELS
September 3, 2016 - September 3, 2017
Co-Chairs: Drs. Gregory Riely and Giorgio Scagliotti

The objective of this activity is to help medical oncologists and other Health Care Professionals (HCPs) understand how to best utilize all three generations of EGFR-directed therapy for NSCLC patients. This includes how to determine the optimal use of each of the three generations of EGFR-directed therapies for specific NSCLC patients based upon the latest data involving various EGFR mutations. In addition, all of the other major variables will be addressed such as optimal sequencing of therapies, single-versus combination therapy, and the use of liquid versus tissue serial biopsies as tools to help guide when EGFR therapy should be changed for a particular patient. This activity provides CME credit to physicians, CNE credit to nurses, CPE credit to pharmacists and a Certificate of Attendance for fellows, and all other HCPs.

This activity is being hosted in association with GRACE
Faculty & Disclosures Information Back to top
Gregory J. Riely, MD, PhD (Co-Chair)
Medical Oncologist, Thoracic Oncology Service
Vice Chair, Clinical Trials Office
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY

Consulting Fees: Genentech/Roche
Contracted Research: Roche, Millennium, Pfizer, Novartis

Giorgio V. Scagliotti, MD, PhD (Co-Chair)
Head, Thoracic Oncology Unit
Department of Clinical and Biological Sciences
University of Turin
San Luigi Hospital
Orbassano, Italy

Consulting Fees: Eli Lilly, AstraZeneca, Roche, Clovis Oncology
Fees for Non-CME/CE Services Received Directly from Commerical Interest or Their Agents (e.g. speakers’ bureaus): Eli Lilly, AstraZeneca

Karen Kelly, MD
Associate Director for Clinical Research
Professor of Medicine
Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon,
Endowed Chair in Cancer Clinical Research
UC Davis Comprehensive Cancer Center
Sacramento, CA

Royalty: UptoDate On-Line Physician Resource Author
Consulting Fees: Synta, Lilly, Clovis, Genentech, AstraZeneca, Ariad, Boehringer Ingelheim
Contracted Research: Millennium, Novartis, EMD Serono, Lilly, Genentech, AbbVie, Giliead, Celgene

I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.

Howard "Jack" West, MD
Medical Director
Thoracic Oncology Program
Swedish Cancer Institute
President and CEO
Global Resource for Advancing Cancer Education
Seattle, WA

Consulting Fees: AstraZeneca, Boehringer Ingelheim, Genentech/Roche, Guardant Health
Fees for Non-CME/CE Services Received Directly from Commerical Interest or Their Agents (e.g. speakers’ bureaus): Genentech/Roche

Heather A. Wakelee, MD
Assistant Professor
Department of Medicine
Division of Oncology
Stanford Cancer Institute
Stanford Comprehensive Cancer Center
Stanford, CA

Consulting Fees: Peregrine, ACEA, Pfizer, Helsinn
Contracted Research: Clovis, Exelixis, AstraZeneca/MedImmune, Genentech/Roche, BMS, Gilead, Novartis, Xcovery, Pfizer, Celgene, Pharmacyclics, Lilly

I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.

LEAD NURSE PLANNER
Diane D. DePew, DSN, RN-BC

I have no real or apparent conflicts of interest to report.

PLANNER & CME/CE REVIEWER
Steve Madison, RPh, MBA (BMLI Manager)

I have no real or apparent conflicts of interest to report.

CME/CE PEER REVIEWER
Danielle Shafer, MD

I have no real or apparent conflicts of interest to report.

Supported by Educational Grants from Clovis Oncology and Boehringer Ingelheim
Educational Needs Back to top

The educational needs addressed by this activity are to help medical oncologists and other Health Care Professionals (HCPs) understand how to best utilize all three generations of EGFR-directed therapy for NSCLC patients. This includes how to determine the optimal use of each of the three generations of EGFR-directed therapies for specific NSCLC patients based upon the latest data involving various EGFR mutations. In addition, all of the other major variables will be addressed such as optimal sequencing of therapies, single-versus combination therapy, and the use of liquid versus tissue serial biopsies as tools to help guide when EGFR therapy should be changed for a particular patient.

Target Audience Back to top

This live activity on June 3, 2016 (including the live “real-time” Internet streaming simulcast} and archived enduring materials for one year) is designed to meet the educational needs of and help close Practice Gaps of medical oncologists, hematologists, radiation oncologists, surgical oncologists, pathologists, oncology pharmacists, oncology nurses/Nurse Practitioners and other allied health-care professionals involved in the treatment, care and management of patients with lung cancer, including physician assistants and fellows. Lung cancer is treated optimally by a multi-disciplinary approach of clinicians and, thus, all of the aforementioned clinician specialties are targeted for invitation to this CME/CE activity for lung cancer patients with EGFR-Positive NSCLC.

Learning Objectives Back to top
PHYSICIAN
  1. Compare and contrast the efficacy, safety, and mechanism of action differences between the first-, second- and third-generation EGFR-directed therapies for EGFR-positive NSCLC patients.
  2. Understand how to use liquid biopsies versus tissue biopsies to optimally sequence EGFR therapies to know when to switch therapies.
  3. Evaluate the pros and cons of using next generation sequencing (NGS) genomic testing panels and their ctDNA liquid biopsy tests.
  4. Analyze EGFR-Treatment-based strategies using monotherapy versus combination therapy for EGFR mutation-positive NSCLC.
NURSE AND PHARMACIST
  1. Recall the efficacy, safety, and mechanism of action differences between the first-, second- and third-generation EGFR-directed therapies for EGFR-positive NSCLC patients.
  2. Review how to use liquid biopsies versus tissue biopsies to optimally sequence EGFR therapies to know when to switch therapies.
  3. List the pros and cons of using next generation sequencing (NGS) genomic testing panels and their ctDNA liquid biopsy tests.
  4. Identify EGFR-Treatment-based strategies using monotherapy versus combination therapy for EGFR mutation-positive NSCLC.
CME/CE Credit Information Back to top

Physicians

The BioMedical Learning Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The BioMedical Learning Institute designates this enduring activity for a maximum of 2 AMA PRA Category 1 Credits™.

Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacists

The BioMedical Learning Institute is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

UAN: 0838-0000-16-002-H01-P
Credits: 2 hours (0.2 ceus)
Type of Activity: Knowledge

To receive CE contact hour credit, attendance at the entire activity and the successful completion of the post‐test and evaluation form is required.

Nurses

The BioMedical Learning Institute is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

The BioMedical Learning Institute designates this educational activity for 2 contact hours.

Accreditation by the American Nurses Credentialing Center's Commission on Accreditation refers to recognition of educational activities and does not imply approval or endorsement of any product.

To receive CE contact hour credit, attendance at the entire activity and the successful completion of the post‐test and evaluation form is required.

Other

Physician Assistants: AAPA accepts certificates of attendance for educational activities certified for Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician Assistants may receive a maximum of 2 hours of Category 1 credit for attending this activity.

Fellows will receive a certificate of attendance that they can submit to their accrediting organizations for continuing education credit.

Agenda Back to top
DEBATE 1: Are There Differences Between First- and Second-Generation EGFR-directed Therapies?
  • There are meaningful differences among the first and second-generation EGFR TKIs- Dr. West
  • First- or second-generation EGFR inhibitor TKIs are interchangeable - Dr. Kelly
Dr. West vs. Dr. Kelly
Q&A and Interactive Panel Discussion and Answering Queued-up Audience Questions
Dr. Riely
Targeting T790M Mutation Positive patients: Clinical developments, challenges and opportunities, including efficacy and toxicity issues
Dr. West
Targeting T790M Mutation Negative patients: Clinical developments, challenges and opportunities, including efficacy and toxicity issues
Dr. Wakelee
EGFR TKIs in Wild Type Patients: Significant differences? Meaningful benefits?
Dr. Riely
DEBATE 2: Tissue Versus Liquid Biopsies to Assess Resistance to EGFR TKIs.
  • Liquid biopsies can sufficiently assess the mechanisms of resistance to EGFR TKIs - Dr. Wakelee
  • Tissue biopsies are the gold standard and cannot yet be replaced - Dr. Scagliotti
Dr. Wakelee vs. Dr. Scagliotti
Q&A and Interactive Panel Discussion and Answering Queued-up Audience Questions
Dr. Scagliotti
Watch Activity Back to top

Not an official event of the 2016 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation.